In Phase 2 trials, retatrutide, a GIP/GLP-1/glucagon based triple agonist, achieved a mean bodyweight reduction of up to 24.2% over 48 weeks
While pharmacotherapies for treatment of obesity prior to GLP-1RAs have had limited impact on cardiovascular outcomes, bariatric surgical procedures have shown long-standing, durable outcomes [7]
Each increase resets the clock, but each successive wave tends to be milder than the last as your GI tract adapts
J Cardiol 1991;21(2):493-504
Reconstituted GHK-Cu only remains stable for 21-30 days refrigerated due to copper oxidation concerns
A very common formula pairs methionine, inositol, choline (the "MIC" core), and L-carnitine with vitamin B1 (thiamine) and vitamin B5 (dexpanthenol)